You are here: Industry Insights > Amgen

News List

Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval fiercepharma
June 06, 2018
With an FDA approval for Fulphila, the first U.S. biosimilar to Amgen's Neulasta, Mylan will have its chance to launch a biosim to one of the biggest drug targets in the U.S. market.
Will Amgen’s migraine win and 5th thumbs-up for Prolia drive enough growth? Nope, says analyst fiercepharma
May 23, 2018
From the looks of it, Amgen is having a bang-up week.
Amgen Receives EC Approval for Repatha americanpharmaceuticalreview
May 18, 2018
Amgen announced that the European Commission (EC) has approved a new indication in the Repatha (evolocumab) label for adults with established atherosclerotic cardiovascular disease
Amgen opens its next-generation workplace in Singapore biospectrumasia
May 16, 2018
Leading new ways of workplace collaboration and connection to enhance innovation, productivity and workplace culture for an agile workplace
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis biospace
April 28, 2018
Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the marketing authorization of Prolia® for the treatment of bone loss associated with long-term systemic
Amgen’s New Products Deliver Double-Digit Growth While Facing Down Pricing Pressure for New Migraine Drug biospace
April 26, 2018
In its first-quarter earnings report, Thousand Oaks, California-based Amgen cited total revenue for the quarter of $5.6 billion, up 2 percent compared to the first quarter of 2017.
Amgen's Migraine Drug Heads Toward Possible May Approval biospace
April 19, 2018
Amgen announced final data from its Phase IIIb LIBERTY clinical trial of Aimovig (erenumab), with positive results likely to lead to a blockbuster drug for migraine sufferers.
Amgen to build first-of-its-kind biomanufacturing plant in the US cphi-online
April 11, 2018
Revolutionary, innovative plant offers greater flexibility, speed and efficiency.
Amgen’s Blincyto gets US approval for acute lymphoblastic leukaemia pharmaceutical-technology
April 09, 2018
Amgen has received approval from the US Food and Drug Administration (FDA) for Blincyto, a drug to treat B-cell precursor acute lymphoblastic leukaemia (ALL) in adults and children.
Amgen Announces Preliminary Results Of Tender Offer biospace
March 07, 2018
Amgen (NASDAQ:AMGN) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 Midnight, New York City time, at the end of March 5, 2018.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page